LUNCA (lutetium (177Lu) chloride) - Radiopharmaceutical precursor

Opinions on drugs - Posted on May 21 2024

Reason for request

First listing

Summary of opinion

Favourable opinion for reimbursement in the MA indication: “LUNCA is a radiopharmaceutical precursor, and it is not intended for direct use in patients. It is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with lutetium (¹⁷⁷Lu) chloride.”

Clinical Benefit

Unspecified

The Committee deems that the clinical benefit of LUNCA (lutetium (¹⁷⁷Lu) chloride) radiopharmaceutical precursor, solution cannot be assessed.

Clinical Added Value

Unspecified

Considering the fact that LUNCA (lutetium (¹⁷⁷Lu) chloride) is a radiopharmaceutical precursor that cannot be assessed without combination with a carrier molecule that has been specifically developed to treat a disease by radionuclide therapy, the Committee deems that the clinical added value of LUNCA (lutetium (¹⁷⁷Lu) chloride) radiopharmaceutical precursor, solution cannot be assessed.